Modality
mAb
MOA
JAK1i
Target
DLL3
Pathway
PD-1/PD-L1
SMADLBCLT2D
Development Pipeline
Preclinical
Jun 2022
→ Jul 2030
PreclinicalCurrent
NCT06985839
1,309 pts·T2D
2022-06→2030-07·Recruiting
NCT06945079
697 pts·T2D
2024-06→2029-02·Not yet recruiting
2,006 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-02-282.9y awayInterim· T2D
2030-07-154.3y awayInterim· T2D
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
Preclinical
Recruit…
Preclinical
Not yet…
Catalysts
Interim
2029-02-28 · 2.9y away
T2D
Interim
2030-07-15 · 4.3y away
T2D
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06985839 | Preclinical | T2D | Recruiting | 1309 | eGFR |
| NCT06945079 | Preclinical | T2D | Not yet recr... | 697 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |